VIDAC PHARMA HOLDING PLC
Commented by Tarik Dede on June 11th, 2026 | 07:05 CEST
Wave of Biotech Acquisitions: Eli Lilly, Vidac Pharma, and GSK in the Spotlight
Cancer remains one of humanity's greatest scourges, and at the same time, it is by far the largest healthcare market of all. But the old-school pharmaceutical giants are running out of oncology pipeline candidates, and now smaller, far more innovative players are increasingly being acquired. The M&A market is currently experiencing extremely dynamic times. This week, for example, GSK announced the acquisition of Nuvalent for USD 10.6 billion in cash. Gilead Sciences, in turn, struck a deal in April with the German company Tubulis—for a total of USD 5 billion. Shortly thereafter, Eli Lilly offered up to USD 7 billion for Kelonia Therapeutics, just to name a few of this year's deals. That is why we are taking a look at the opportunities in the sector today and putting the stocks of Eli Lilly, Vidac Pharma, and GSK under the microscope!
Read
Commented by Armin Schulz on June 3rd, 2026 | 07:25 CEST
Opportunities in the Oncology Market: Positioning for the Next Billion-Dollar Catalyst with BioNTech, Vidac Pharma, and Pfizer
An aging population is driving rapid increases in healthcare spending. A trillion-dollar market is emerging in the cancer sector, as over 30 million new cases are expected annually by 2040. As traditional chemotherapy approaches its limits, new technologies and ideas are needed. Those who set the course today can benefit from this transformation, even if not every approach will succeed. The key question remains: which companies possess the key technologies to benefit from this boom? Three players are coming into particular focus: BioNTech with its mRNA platform, Vidac Pharma with a patented metabolic approach, and Pfizer with its multi-billion-dollar acquisitions.
Read
Commented by Fabian Lorenz on May 26th, 2026 | 07:30 CEST
Caution with BioNTech! Novo Nordisk Accelerates! Buying Opportunity in Vidac Pharma Stock?
Investor sentiment around Novo Nordisk is improving. Shares of the Danish pharmaceutical giant appear to be breaking out of the downtrend that began in the summer of 2024, with investors responding positively to recent developments. At Vidac Pharma, the latest announcement seems to have gone largely unnoticed. Yet it could mark the beginning of interest from strategic investors. There is even speculation about a potential full takeover of the oncology specialist. With a market capitalization of only around EUR 33 million, any acquisition would likely require a substantial premium. While investors may be knocking on Vidac's door, sentiment toward BioNTech has deteriorated. The company's founding couple is stepping down, and locations are being closed. And now analysts are also questioning the quality of the company's product pipeline.
Read
Commented by André Will-Laudien on May 21st, 2026 | 07:10 CEST
Undervalued – Analysts Turn Their Attention to Life Sciences: Bayer, Vidac Pharma, Novo Nordisk, and Pfizer in Focus
DZ Bank's aggressive price target adjustment for Bayer demonstrates that analysts have recently begun to view the life sciences sector more favourably. The pharmaceutical and agrochemical group's strong start to the year has led to significantly improved prospects, and legal risks are now also viewed as more moderate. Finally, some good news for long-suffering investors in a geopolitically volatile environment. After all, there have not been any major upgrades in the sector for quite some time. When it comes to Novo Nordisk, however, experts remain divided on whether the earnings trend will turn positive again. Cutthroat competition in the weight-loss drug market is intense, putting pressure on margins. Buoyed by industry sentiment, Pfizer also saw its stock rise again. Time for a new tour of the sector. Where are the triggers?
Read
Commented by Nico Popp on May 14th, 2026 | 07:50 CEST
Checkmate for Cancer: What Eli Lilly and Bayer Can Learn from Vidac Pharma
Modern medicine is on the cusp of groundbreaking innovations in which the regulation of cellular energy metabolism, known as metabolic correction, is becoming a decisive strategy. While traditional cancer research has relied primarily on the destruction of cells using toxic agents for decades, researchers now recognize that the key to success may lie in the precise control of enzymatic processes. In light of this, value creation is shifting away from the conventional "sledgehammer approach" toward correcting cellular dysregulation. We highlight three exciting companies and focus in particular on metabolism pioneer Vidac Pharma.
Read
Commented by Armin Schulz on April 30th, 2026 | 07:00 CEST
Weight-Loss Injections, Cancer Cell Inhibitors & the Power of Algorithms: Adding Potential to Your Portfolio with Novo Nordisk, Vidac Pharma, and Evotec
The healthcare market faces a paradoxical scenario in 2026. Public health funds are groaning under record spending, while groundbreaking technologies are redefining medicine. AI-driven drug discovery and personalized therapies promise efficiency gains, but regulatory hurdles and price wars are causing stock prices to fluctuate. In this complex landscape, the wheat is being separated from the chaff. Three distinct biotech strategies could now provide the decisive edge. Novo Nordisk dominates the mass market for metabolic diseases, Vidac Pharma is tackling cancer in novel ways, and Evotec is digitizing the entire drug discovery process.
Read
Commented by Fabian Lorenz on April 20th, 2026 | 08:10 CEST
Insider Sales, Buy Ratings, and AI Momentum: BioNTech, Evotec, and Vidac Pharma in Focus
Insider sales at Vidac Pharma. However, this is not necessarily a cause for concern and may rather present a potential entry opportunity. The company is working on a revolutionary cancer therapy, with key milestones expected in 2026. Analysts see significant upside potential, and there is also speculation about a possible takeover. AI-driven expectations are giving Evotec shares new momentum. Analysts recommend buying the stock, although there are also reasons for caution. At BioNTech, the market appears to have absorbed the impact of the founders' departure. Following positive study data, analysts see further upside potential.
Read
Commented by Mario Hose on April 13th, 2026 | 07:30 CEST
100% Profit Potential in Sight: Vidac Pharma's Chance to Double vs Bayer and Evotec
Even in the spring of 2026, the stock market remains highly volatile. The upheavals caused by geopolitical crises have been and remain significant and ever-present. While heavyweights like Bayer are struggling to shake off their legal baggage and Evotec is steering into calmer waters, a stock from the back row is suddenly stepping into the spotlight. Vidac Pharma has also had a few turbulent months, and this is precisely where experienced investors now sense an opportunity. With a current share price of EUR 0.56, the company is poised for a potential recovery, an uptick, and perhaps even a complete revaluation. If the strategy pays off, the EUR 1 mark could be reached. That would be a chance to double their money for bold investors. But what is behind this optimism? In this report, we take a look at the industry giants and analyze not only them but also why, of all three, the one with the smallest market capitalization could develop the greatest momentum. It is about potential breakthroughs in cancer research and a management team that is optimizing many aspects for success.
Read
Commented by Carsten Mainitz on April 10th, 2026 | 08:20 CEST
Unlocking Massive Potential in Pharma's Largest Segment: Innovator Vidac Pharma, Industry Leader Bayer, or Turnaround Candidate Evotec?
Oncology is the most strategically important growth market in the pharmaceutical industry and at the same time one of the key levers for improving global health. Currently, around 20 million people worldwide are diagnosed with cancer each year, a figure expected to exceed 30 million annually by 2040. The global oncology drug market is already valued at over USD 200 billion and continues to expand rapidly. Bayer aims to rank among the world's leading oncology players by 2030 and recently reaffirmed its medium-term targets. Following the sale of a stake in a cancer specialist, shareholders of Evotec, which has faced significant pressure, may soon benefit from a welcome inflow of funds. Vidac Pharma, on the other hand, is breaking new ground in the fight against skin cancer. There is enormous potential here.
Read
Commented by Nico Popp on March 30th, 2026 | 08:30 CEST
A Paradigm Shift in Oncology: Core Stocks Roche & Galderma and the High-Leverage Opportunity in Vidac Pharma
Medical advances affect us all. Oncology is also undergoing a transformation. As conventional immunotherapies for skin cancer increasingly reach their limits, clinical research is shifting its focus to correcting defective tumor metabolism. The Warburg effect, where cancer cells shift energy production to aerobic glycolysis to fuel uncontrolled growth, offers a promising entry point. This dynamic development landscape is exacerbated by an impending patent cliff, which, according to calculations by the consulting firm PwC, threatens industry revenues of USD 104 billion by 2028, as many patents for active ingredients are expiring. Currently, market researchers at Fortune Business Insights estimate the volume of the global oncology market for 2026 at USD 286.36 billion. While pharmaceutical giant Roche secures its market leadership and the Galderma Group dominates standard dermatological care, biotechnology company Vidac Pharma is targeting the metabolic vulnerability of cancer cells with a completely novel mechanism of action, aiming to effectively shut down the cancer.
Read